Vivos (RDGL) Income towards Parent Company (2010 - 2025)
Vivos (RDGL) reported Income towards Parent Company of -$1.1 million for Q4 2025, down 5.41% on a YoY basis from -$1.1 million in Q4 2024, and down 112.6% sequentially from -$507294.0 in Q3 2025.
Vivos (RDGL) Income towards Parent Company (2010 - 2025) Analysis & Trends
Vivos (RDGL) has 16 years of Income towards Parent Company data on file, last reported at -$1.1 million in Q4 2025.
- For the quarter ending Q4 2025, Income towards Parent Company fell 5.41% year-over-year to -$1.1 million; the trailing twelve-month figure through Dec 2025 stood at -$3.1 million (down 5.35% YoY), and the FY2025 full-year result was -$3.1 million, down 5.35% from the prior year.
- Income towards Parent Company declined to -$1.1 million in Q4 2025, from -$507294.0 in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$178230.0 in Q4 2021 to a low of -$1.9 million in Q2 2021.
- A 5-year average of -$693457.2 and a median of -$683797.5 in 2022 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company sank 1069.29% in 2021 and jumped 64.52% in 2023, its largest moves.
- Tracing RDGL's Income towards Parent Company over 5 years: stood at -$178230.0 in 2021, then plunged by 295.92% to -$705653.0 in 2022, then slumped by 52.51% to -$1.1 million in 2023, then climbed by 4.93% to -$1.0 million in 2024, then fell by 5.41% to -$1.1 million in 2025.
- Business Quant data shows RDGL's Income towards Parent Company at -$1.1 million in Q4 2025, -$507294.0 in Q3 2025, and -$645513.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.88 Bn | 176.59 Bn | 6.27 Bn |
| 2 | Stryker | 128.94 Bn | 126.06 Bn | 3.81 Bn |
| 3 | Medtronic | 108.75 Bn | 99.53 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.65 Bn | 67.19 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.22 Bn | 44.55 Bn | 1.29 Bn |
| 6 | Dexcom | 28.43 Bn | 27.31 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.32 Bn | 26.03 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.91 Bn | 26.33 Bn | - |
| 9 | Koninklijke Philips | 25.10 Bn | 21.98 Bn | 2.07 Bn |
| 10 | Vivos | 27.62 Mn | 26.06 Mn | -3,105.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.08 Mn |
| Sep 30, 2025 | -507,294.00 |
| Jun 30, 2025 | -645,513.00 |
| Mar 31, 2025 | -834,696.00 |
| Dec 31, 2024 | -1.02 Mn |
| Sep 30, 2024 | -825,263.00 |
| Jun 30, 2024 | -503,458.00 |
| Mar 31, 2024 | -558,539.00 |
| Dec 31, 2023 | -1.08 Mn |
| Sep 30, 2023 | -667,690.00 |
| Jun 30, 2023 | -902,526.00 |
| Mar 31, 2023 | -248,318.00 |
| Dec 31, 2022 | -705,653.00 |
| Sep 30, 2022 | -277,065.00 |
| Jun 30, 2022 | -787,538.00 |
| Mar 31, 2022 | -699,905.00 |
| Dec 31, 2021 | -178,230.00 |
| Sep 30, 2021 | -201,160.00 |
| Jun 30, 2021 | -1.86 Mn |
| Mar 31, 2021 | -288,189.00 |